New drug candidate takes on Hard-to-Treat myeloma

NCT ID NCT04000282

Completed Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-stage trial tested an experimental drug called SAR442085 in 37 people with multiple myeloma that had returned or stopped responding to prior treatments. The main goals were to find a safe dose and check for any signs that the drug shrinks tumors. Participants received the drug by IV infusion, and researchers monitored side effects and how the drug moved through the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SAR442085 (an experimental drug given by IV infusion)
What this could lead to: If successful, this could lead to a new treatment option for people with multiple myeloma that has stopped responding to other therapies.
What could go wrong: This is a very early Phase 1 trial with only 37 people, so it is primarily testing safety and dosing. The drug may not work well or could have serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PLASMA CELL MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PLASMA CELL MYELOMA

Contacts and locations

Locations

City of Hope Site Number : 8400002

Duarte, California, 91010, United States
Dana Farber Cancer Institute Site Number : 8400003

Boston, Massachusetts, 02115, United States
Froedtert Hospital & Medical College of Wisconsin Site Number : 8400004

Milwaukee, Wisconsin, 53226, United States
Investigational Site Number : 1580001

Taipei, 10002, Taiwan
Investigational Site Number : 2030001

Prague, 12808, Czechia
Investigational Site Number : 2030002

Brno, 62500, Czechia
Investigational Site Number : 2030003

Ostrava - Poruba, 70852, Czechia
Investigational Site Number : 2500001

Toulouse, 31059, France
Investigational Site Number : 3000001

Athens, 11528, Greece
Investigational Site Number : 7240001

Salamanca, Salamanca, 37007, Spain
Mayo Clinic of Rochester Site Number : 8400005

Rochester, Minnesota, 55905, United States
UNC Chapel Hill Site Number : 8400006

Chapel Hill, North Carolina, 27599, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.